Nicotine, but neither the alpha4beta2 ligand RJR2403 nor an alpha7 nAChR subtype selective agonist, protects against a partial 6-hydroxydopamine lesion of the rat median forebrain bundle - PubMed (original) (raw)
Comparative Study
Nicotine, but neither the alpha4beta2 ligand RJR2403 nor an alpha7 nAChR subtype selective agonist, protects against a partial 6-hydroxydopamine lesion of the rat median forebrain bundle
N P Visanji et al. Neuropharmacology. 2006 Sep.
Abstract
Although previous studies suggest nicotine protects against a 6-hydroxydopamine (6-OHDA)-induced lesion of the nigrostriatal tract in rats, it is not known whether functional motor recovery occurs or which nicotinic acetylcholine receptor (nAChR) subtypes mediate this effect. These issues were investigated by comparing the effects of the subtype-specific nAChR agonists, RJR2403 (alpha4beta2 preferring) and (R)-N-(1-azabicyclo[2.2.2.]oct-3-yl)(5-(2-pyridyl)thiopene-2-carboxamide (Compound A; alpha7-selective) and nicotine given 30 min prior to and daily for 14 days after a partial 6-OHDA lesion. In vehicle treated animals, 6-OHDA (6 microg) produced a 65 +/- 1.8% loss of striatal tyrosine hydroxylase (TH) immunoreactivity in the lesion versus intact hemisphere. This loss was reduced in animals treated with nicotine (0.6 and 0.8 mg kg(-1)), reaching significance at the higher dose (36.6 +/- 3.7% loss; P < 0.01 versus vehicle). Treatment with nicotine (0.6 and 0.8 mg kg(-1)) also significantly reduced the number of amphetamine-induced rotations compared to vehicle treatment. In contrast, treatment with RJR2403 (0.2 and 0.4 mg kg(-1)) or Compound A (10 and 20 mg kg(-1)) reduced neither the degree of amphetamine-induced rotations nor the loss of striatal TH immunoreactivity. These data suggest that whilst nicotine is neuroprotective in this partial lesion model, activation of neither the alpha4beta2 nor alpha7 subtypes alone is sufficient to provide protection.
Similar articles
- Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease.
Yuan H, Sarre S, Ebinger G, Michotte Y. Yuan H, et al. J Neurosci Methods. 2005 May 15;144(1):35-45. doi: 10.1016/j.jneumeth.2004.10.004. Epub 2004 Dec 8. J Neurosci Methods. 2005. PMID: 15848237 - Synergistic effect of galantamine on nicotine-induced neuroprotection in hemiparkinsonian rat model.
Yanagida T, Takeuchi H, Kitamura Y, Takata K, Minamino H, Shibaike T, Tsushima J, Kishimoto K, Yasui H, Taniguchi T, Shimohama S. Yanagida T, et al. Neurosci Res. 2008 Dec;62(4):254-61. doi: 10.1016/j.neures.2008.09.003. Epub 2008 Sep 20. Neurosci Res. 2008. PMID: 18845194 - Nicotine alters striatal glutamate function and decreases the apomorphine-induced contralateral rotations in 6-OHDA-lesioned rats.
Meshul CK, Kamel D, Moore C, Kay TS, Krentz L. Meshul CK, et al. Exp Neurol. 2002 May;175(1):257-74. doi: 10.1006/exnr.2002.7900. Exp Neurol. 2002. PMID: 12009777 - Neuroprotective effect of nicotine against 3-nitropropionic acid (3-NP)-induced experimental Huntington's disease in rats.
Tariq M, Khan HA, Elfaki I, Al Deeb S, Al Moutaery K. Tariq M, et al. Brain Res Bull. 2005 Sep 30;67(1-2):161-8. doi: 10.1016/j.brainresbull.2005.06.024. Brain Res Bull. 2005. PMID: 16140176 - Synthetic Methods for the Preparation of Conformationally Restricted Analogues of Nicotine.
Panda B, Albano G. Panda B, et al. Molecules. 2021 Dec 13;26(24):7544. doi: 10.3390/molecules26247544. Molecules. 2021. PMID: 34946630 Free PMC article. Review.
Cited by
- Nicotine-mediated effects in neuronal and mouse models of synucleinopathy.
Fares MB, Alijevic O, Johne S, Overk C, Hashimoto M, Kondylis A, Adame A, Dulize R, Peric D, Nury C, Battey J, Guedj E, Sierro N, Mc Hugh D, Rockenstein E, Kim C, Rissman RA, Hoeng J, Peitsch MC, Masliah E, Mathis C. Fares MB, et al. Front Neurosci. 2023 Aug 31;17:1239009. doi: 10.3389/fnins.2023.1239009. eCollection 2023. Front Neurosci. 2023. PMID: 37719154 Free PMC article. - Nicotine as a potential neuroprotective agent for Parkinson's disease.
Quik M, Perez XA, Bordia T. Quik M, et al. Mov Disord. 2012 Jul;27(8):947-57. doi: 10.1002/mds.25028. Epub 2012 Jun 12. Mov Disord. 2012. PMID: 22693036 Free PMC article. Review. - Stereotaxical infusion of rotenone: a reliable rodent model for Parkinson's disease.
Xiong N, Huang J, Zhang Z, Zhang Z, Xiong J, Liu X, Jia M, Wang F, Chen C, Cao X, Liang Z, Sun S, Lin Z, Wang T. Xiong N, et al. PLoS One. 2009 Nov 18;4(11):e7878. doi: 10.1371/journal.pone.0007878. PLoS One. 2009. PMID: 19924288 Free PMC article. - Chronic nicotine treatment increases nAChRs and microglial expression in monkey substantia nigra after nigrostriatal damage.
Quik M, Campos C, Parameswaran N, Langston JW, McIntosh JM, Yeluashvili M. Quik M, et al. J Mol Neurosci. 2010 Jan;40(1-2):105-13. doi: 10.1007/s12031-009-9265-9. Epub 2009 Aug 15. J Mol Neurosci. 2010. PMID: 19685015 Free PMC article. - Nicotine-Induced Neuroprotection in Rotenone In Vivo and In Vitro Models of Parkinson's Disease: Evidences for the Involvement of the Labile Iron Pool Level as the Underlying Mechanism.
Mouhape C, Costa G, Ferreira M, Abin-Carriquiry JA, Dajas F, Prunell G. Mouhape C, et al. Neurotox Res. 2019 Jan;35(1):71-82. doi: 10.1007/s12640-018-9931-1. Epub 2018 Jul 13. Neurotox Res. 2019. PMID: 30006684
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources